GILD News and Press, Gilead Sciences Inc. From 06/23/24

2024-06-23 12:49:01 ET More on the markets SPY: The Upside Is Likely Capped SPY: Rating Downgrade Due To Overvaluation Perfect Time For November Election Protection S&P posts three-week win streak, but momentum stalls after hitting 5,500 points mark ...

2024-06-23 09:01:47 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...

2024-06-22 03:56:43 ET Summary Gilead Sciences reports positive Phase III trial results for lenacapavir, showing zero incident cases of HIV infection in the treatment group. Results suggest the potential for lenacapavir to revolutionize HIV prevention and treatment, leading to mar...

2024-06-21 09:06:00 ET U.S. stock index futures on Friday pointed to a marginally lower open, a day after Wall Street's rally stalled following another historic milestone. Here are some stocks to watch on Friday: ... Read the full article on Seeking Alpha For further de...

2024-06-20 14:00:04 ET Brian Skorney from Robert W. Baird issued a price target of $80.00 for GILD on 2024-06-20 11:18:00. The adjusted price target was set to $80.00. At the time of the announcement, GILD was trading at $69.21. The overall price target consensus is at $...

2024-06-20 13:00:43 ET Summary Ironwood Pharmaceuticals, Inc. data from the phase 2 proof-of-concept study, using CNP-104 for the treatment of patients with primary biliary cholangitis, expected in Q3 of 2024. The global primary biliary cholangitis therapeutics market size is proj...

Gilead Sciences, Inc. (NASDAQ: GILD) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 7.74% on the day to $68.04. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in th...

2024-06-20 10:00:20 ET More on Gilead Sciences Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Gilead Sciences, Inc. (GILD) Jefferies 2024 Global Healthcare Conference Gilead Sciences: Seriously Undervalued At Peak Pes...

– First Phase 3 HIV Prevention Trial Ever to Show Zero Infections – – Independent Data Monitoring Committee Recommended That Gilead Stop the Blinded Phase of the PURPOSE 1 Trial at Interim Analysis and Offer Open-Label Lenacapavir to All Participants – ...

2024-06-20 08:45:59 ET Palm Beach, FL – June 20, 2024  – Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocar...